Oral administration of 100 mg KH176 twice daily
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mitochondrial Diseases
Conditions
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS), Chronic Progressive External Ophthalmoplegia (CPEO)
Trial Timeline
Aug 9, 2021 → Jun 1, 2023
NCT ID
NCT04604548About Oral administration of 100 mg KH176 twice daily
Oral administration of 100 mg KH176 twice daily is a phase 2 stage product being developed by Certara for Mitochondrial Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT04604548. Target conditions include Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04604548 | Phase 2 | Completed |
Competing Products
13 competing products in Mitochondrial Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Mavodelpar + Placebo | OnKure Therapeutics | Phase 2 | 44 |
| REN001 | OnKure Therapeutics | Phase 2/3 | 57 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 2 | 52 |
| Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg | AbbVie | Phase 2 | 52 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 51 |
| Vatiquinone | PTC Therapeutics | Phase 2/3 | 62 |
| EPI-743 | PTC Therapeutics | Pre-clinical | 20 |
| RG2133 (2',3',5'-tri-O-acetyluridine) | Repligen | Phase 1 | 30 |
| Vatiquinone | PTC Therapeutics | Pre-clinical | 20 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 74 |
| Sonlicromanol + Placebo | Certara | Phase 2 | 47 |